Australia-based healthcare startup Heidi announced the close of a $100 million (A$140 million) Series C funding round led by Blackbird.
The round values the firm at $900 million (A$1.26 billion).
Existing investors, including Phoenix Court, Point72 Private Investments, and Headline, also participated in this round.
Alongside the equity round, Heidi has also secured a $240 million (A$335 million) growth investment led by General Catalyst’s Customer Value Fund (CVF), providing go-to-market financing to back Heidi’s rapid growth and scale.
This brings the total new funding to $340 million.
The investment supports Heidi’s next phase of growth: deepening adoption across global health systems, bringing agentic capabilities to support the work around patient visits, and continuing to build the regulatory and clinical safety foundations those capabilities require.
“From the day I started Heidi, the ambition was always bigger than writing doctors’ notes. I imagined that AI would sit alongside clinicians and complete real work under their supervision,” said Dr Thomas Kelly, Co-founder and CEO of Heidi. “That’s the shift we’re now making: from documenting care to helping clinicians act on it. This round is about getting an AI Care Partner to every doctor in the world, and putting clinicians back at the center of care with their patients.”
Heidi is building an AI Care Partner that supports clinicians across the whole working day, from administration and clinical knowledge to the work around the patient visit.
The company claims that its AI Care Partner has supported more than 175 million patient visits (up from 73 million at Series B), and over 67 million clinical hours, more than tripling since September 2025. Annual recurring revenue grew from $1 million to $50 million (April 2026) in just two years.
Part of this round also funds the clinical evidence, quality management systems and regulatory submissions that agentic capability in healthcare demands.
“We’ve backed Tom and the team since their pre-seed in 2021 and our conviction is greater than ever. The healthcare deficit won’t be solved with generic AI solutions that clinicians ignore. Heidi invested early in deeply understanding what clinicians want, building its own models and training capability to deliver this. This approach has earned them the right to capture valuable downstream workflows in the most rigorous clinical settings globally,” said Michael Tolo, General Partner, Blackbird.
Founded in Melbourne, Heidi has so far raised $436.6 million from global investors including Blackbird, General Catalyst, Phoenix Court (the home of LocalGlobe, Latitude and Solar funds), Point72 Private Investments, Headline, Possible Ventures, Glitch Capital and Archangel.
In October last year, Heidi closed a $65-million Series B funding round, led by Point72 Private Investments. The Australian healthcare AI firm also announced it will invest up to $8 million over the next three years to build a regional hub in Singapore.
